RE:RE:Publication Thev`ve obviously tried to get further indications partnered by Pharma without success:
‘The potential approval of TLD-1433 in the coming years may pave the way for clinical investigation of other Ru(II)-based complexes, which have remained in preclinical stages for a protracted time. We hope that the pharmaceutical industry will be less reticent to finance such expensive studies, due to the success of a compound of the same family.’